This edition of Orphan Drugs & Rare Diseases Global Congress Europe has already taken place.

Search future editions →

Events Healthcare & MedTech

Healthcare & MedTech

Orphan Drugs & Rare Diseases Global Congress Europe 2025

23rd edition

Trade-orientedBoutiqueIn-personInternational draw
📅 19 March 2025 – 20 March 📍 Copthorne Tara Hotel London Kensington, London, GB ↗ 🏢 Facilitate Live 🔁 annual

50

Exhibitors

100

Attendees

An international congress focused on the regulatory, commercial, and clinical challenges of orphan drug development and rare disease treatments. Brings together pharmaceutical executives, biotechnology companies, patient advocacy groups, and global healthcare regulatory authorities.

Exhibitor mix: Organized flatly by tier including Headline Sponsors, Gold Sponsors, and Exhibition Stand partners on a dedicated event subpage.

Pharma BiotechHealthcare Services orphan drugsrare diseasesbiotechnologypharmaceuticalsdrug developmentpatient advocacyregulatory affairsclinical trials

Filter this event to your ICP.

50 exhibitors here. You probably care about 20–30. Tell us your ICP, we'll find them.

Request intelligence →

Delivery within 24 hours · $1,250

Venue

Copthorne Tara Hotel London Kensington

Hotel venue · 1 halls · ~400 people

A 4-star hotel in Kensington, London, featuring extensive event spaces including the Tara Ballroom, catering to meetings, conferences, and corporate events.

📍 Scarsdale Pl, London W8 5SR, UK

Operated by Millennium & Copthorne Hotels

3 events tracked at this venue → Venue website ↗

Organizer

Facilitate Live

Private · London, United Kingdom · Founded 2013

Organizer of high-level pharmaceutical and biotechnology conferences, specializing in rare diseases and orphan drugs.

Runs 3 events →

Why people attend

Buyers attend to explore early access program partnerships, evaluate real-world evidence data extraction platforms, align with clinical trial recruitment providers, and establish strategic alliances with rare disease advocacy leaders.

Who attends

Pharmaceutical and biotech executivesclinical research professionalspatient advocacy group leadersgeneticistsand medical/regulatory affairs directors.

Exhibitor categories

Contract Research OrganizationsReal-World Evidence PlatformsSpecialist Early Access ProvidersOrphan Drug LogisticsPatient Advocacy Networks

Sample matches

Filtered to a Series-B SaaS ICP. Your filter will be different.

Sample Match A

example.com

91 — High
Enterprise SaaS200–500 employeesAmsterdam, NL

"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."

Sample Match B

example.io

79 — Medium
Cloud platform50–200 employeesLondon, UK

"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."

████████ ██████

████████.io

██ — Medium
████████████ 200–500 employees ████, ██

"████████████████████████████████████████."

Submit your ICP
to unlock all matches

Request intelligence →

████████ ██████

████████.io

██ — Medium
████████████ 200–500 employees ████, ██

"████████████████████████████████████████."

Submit your ICP
to unlock all matches

Request intelligence →

Speakers

42 speakers at Orphan Drugs & Rare Diseases Global Congress Europe

S

Stefano Benvenuti

Head of Public Affairs and Market Access · Fondazione Telethon

"Progressing Rare disease diagnosis, care and treatment to improve health outcomes for patients with rare diseases"

rare disease diagnosishealth outcomesmarket access
A

Alexander Natz

Secretary General · EUCOPE

"Reflections on the EU’s future rare disease policy environment"

rare disease policyEU legislationOMP landscape

Also speaking at BIO Middle East 2026

D

Dr James Levine

President · Fondation Ipsen

"The DACMAR Advantage: This approach helps biotech companies position themselves for potential acquisition or public offering, with a focus on creating sustainable impact and preparing for long-term success"

biotech acquisitionsustainable impactDACMAR approach
D

Dr. Femida Gwadry-Sridhar

Founder and CEO · Pulse infoframe Inc.

"Answering the million dollar question: Who really owns the data?"

data ownershippatient datahealthcare data agreements
D

Dr. Rüdiger Schulze

Vice President and General Manager, DACH · Ultragenyx

"Early access to Orphan Drugs in Europe"

orphan drugsearly accessEuropean regulations
M

Manel Cascalló

General Director EU Subsidiary & Founder · Theriva Biologics

"VCN-01 oncolytic adenovirus development in pediatric retinoblastoma"

oncolytic adenoviruspediatric retinoblastomaclinical data
J

Jennifer Schranz

SVP, Global Head of Rare Diseases · Ipsen

"Scientific journey from coal to diamond: myths and misperceptions in rare disease innovation"

rare disease innovationmedicines developmentvalue of innovation
A

Anthony Hall

Co-Founder, Member of Board & Scientific Advisor · Beacon for Rare Diseases

"Mesenchymal stem cells as a potential treatment for osteogenesis imperfecta"

mesenchymal stem cellsosteogenesis imperfectapediatric drug development

Also speaking at International Security Conference & Exposition East

P

Prof Guillaume Canaud

Translational Medicine and Targeted Therapies Unit · Necker Enfants Malades

"Drug repositioning in overgrowth syndrome and vascular malformations"

drug repositioningovergrowth syndromevascular malformations

Also speaking at 56th Annual ESDR Meeting

S

Surabhi Verma

Chief Medical Officer · Leadiant Biosciences

"Promises and Pitfalls of using Real World Data and Evidence (RWD/E) in Orphan Drug Development.**"

real world dataorphan drug developmentRWD/E pitfalls
S

Stacey Minton

SVP, Head of Corporate Affairs · Kyowa Kirin International

"Chairpersons Welcome and Opening Remarks"

corporate affairsrare disease accessopening remarks
D

Dr Pooja Takhar

Joint Chief Executive · Tuberous Sclerosis Association

"Rare Diseases and Orphan Drugs: The importance of Patient engagement strategies to overcome challenges in Orphan Drug Development"

patient engagementclinical trialsorphan drug development
U

Usman Khan

Chair · Motor Neurone Disease (MND) Association

"Reframing the patient in an age of precision medicine"

precision medicinepatient advocacydisease subpopulations
D

"Defining rare in the era of personalised medicine"

pharmaceutical compliancemedical device ethics

Also speaking at 27th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress

D

Dr Peter Davis

Chair, BPSU, Scientific Committee · Bristol Royal Hospital for Children

"Rare diseases – not just the “what” but the “who”"

rare disease epidemiologygenomicsdisease surveillance
N

Nick Sireau

CEO and Chair of Trustees · AKU Society

"Challenges and opportunities for mRNA therapy for rare genetic diseases"

mRNA therapyalkaptonuriarare genetic diseases

+ 26 more speakers at this event.

More Healthcare & MedTech events

Healthcare & MedTech

Pharma Manufacturing World Summit

Boston, US May 2027

Healthcare & MedTech

REHAB

Karlsruhe, DE May 2027

400 exhibitors

Healthcare & MedTech

Vitafoods Europe

Barcelona, ES May 2027

1,600 exhibitors

Healthcare & MedTech

World Vaccine Congress Washington

Washington D.C., US Mar 2027

More Healthcare & MedTech events

All Healthcare & MedTech trade showsAll events in United Kingdom

Frequently asked questions

When is Orphan Drugs & Rare Diseases Global Congress Europe?+
Orphan Drugs & Rare Diseases Global Congress Europe takes place on 19 March 2025 to 20 March 2025.
Where is Orphan Drugs & Rare Diseases Global Congress Europe held?+
Orphan Drugs & Rare Diseases Global Congress Europe is held at Copthorne Tara Hotel London Kensington, London, GB.
Who organises Orphan Drugs & Rare Diseases Global Congress Europe?+
Orphan Drugs & Rare Diseases Global Congress Europe is organised by Facilitate Live.
How many exhibitors attend Orphan Drugs & Rare Diseases Global Congress Europe?+
Orphan Drugs & Rare Diseases Global Congress Europe typically hosts approximately 50 exhibitors.
How often is Orphan Drugs & Rare Diseases Global Congress Europe held?+
Orphan Drugs & Rare Diseases Global Congress Europe is held annual.

Ready to map Orphan Drugs & Rare Diseases Global Congress Europe?

Request intelligence →